Biofrontera 미래 성장

Future 기준 확인 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Biofrontera.

주요 정보

n/a

수익 성장률

n/a

EPS 성장률

Pharmaceuticals 수익 성장	18.0%
매출 성장률	n/a
향후 자기자본 수익률	n/a
애널리스트 커버리지	None
마지막 업데이트	n/a

최근 미래 성장 업데이트

Recent updates

Biofrontera AG (ETR:B8FK) Surges 30% Yet Its Low P/S Is No Reason For Excitement

Oct 13

Biofrontera AG (ETR:B8FK) Not Doing Enough For Some Investors As Its Shares Slump 47%

May 21

Why Investors Shouldn't Be Surprised By Biofrontera AG's (ETR:B8F) 30% Share Price Plunge

Mar 07

We're Keeping An Eye On Biofrontera's (ETR:B8F) Cash Burn Rate

Feb 19

Here's Why It's Unlikely That Biofrontera AG's (ETR:B8F) CEO Will See A Pay Rise This Year

Dec 07

Does Biofrontera (ETR:B8F) Have A Healthy Balance Sheet?

Jun 08

Biofrontera AG (ETR:B8F) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Apr 14

이 섹션에서는 일반적으로 투자자가 회사의 수익 창출 능력을 이해하는 데 도움이 되도록 전문 애널리스트의 컨센서스 추정치를 기반으로 수익 및 수익 성장 전망치를 제시합니다. 하지만 Biofrontera 은 충분한 과거 데이터를 제공하지 않았고 애널리스트 예측도 없기 때문에 과거 데이터를 추정하거나 애널리스트 예측을 사용하여 미래 수익을 안정적으로 계산할 수 없습니다.

SimplyWall St에서 다루는 기업의 97%가 과거 재무 데이터를 가지고 있기 때문에 이는 매우 드문 상황입니다.

수익 및 매출 성장 예측

XTRA:B8FK - 애널리스트의 미래 추정치 및 과거 재무 데이터 (EUR Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
6/30/2024	22	-3	-5	-4	N/A
3/31/2024	30	0	N/A	N/A	N/A
12/31/2023	32	0	-3	-2	N/A
9/30/2023	29	-9	N/A	N/A	N/A
6/30/2023	28	-11	-4	-3	N/A
3/31/2023	25	-20	N/A	N/A	N/A
12/31/2022	26	-44	-5	-4	N/A
9/30/2022	32	11	N/A	N/A	N/A
6/30/2022	31	10	33	33	N/A
3/31/2022	30	15	N/A	N/A	N/A
12/31/2021	29	38	30	30	N/A
9/30/2021	28	-16	N/A	N/A	N/A
6/30/2021	27	-16	-8	-7	N/A
3/31/2021	29	-12	N/A	N/A	N/A
12/31/2020	30	-13	-4	-3	N/A
9/30/2020	33	-17	N/A	N/A	N/A
6/30/2020	33	-22	-14	-12	N/A
3/31/2020	31	-10	N/A	N/A	N/A
12/31/2019	31	-7	-35	-33	N/A
9/30/2019	26	1	N/A	N/A	N/A
6/30/2019	26	8	-29	-28	N/A
3/31/2019	23	-8	N/A	N/A	N/A
12/31/2018	21	-9	-14	-13	N/A
9/30/2018	19	-14	-13	-13	N/A
6/30/2018	16	-15	-12	-12	N/A
3/31/2018	14	-16	N/A	N/A	N/A
12/31/2017	12	-16	N/A	-13	N/A
9/30/2017	11	-18	N/A	-16	N/A
6/30/2017	9	-16	N/A	-16	N/A
3/31/2017	8	-14	N/A	-15	N/A
12/31/2016	6	-11	N/A	-10	N/A
9/30/2016	4	-9	N/A	-8	N/A
6/30/2016	4	-7	N/A	-6	N/A
3/31/2016	4	-9	N/A	-8	N/A
12/31/2015	4	-11	N/A	-10	N/A
9/30/2015	4	-12	N/A	-10	N/A
6/30/2015	3	-13	N/A	-10	N/A
3/31/2015	3	-10	N/A	-7	N/A
12/31/2014	3	-11	N/A	-8	N/A
9/30/2014	3	-10	N/A	-8	N/A
6/30/2014	3	-10	N/A	-7	N/A
3/31/2014	3	-9	N/A	-7	N/A
12/31/2013	3	-8	N/A	-7	N/A

애널리스트 미래 성장 예측

수입 대 저축률: Insufficient data to determine if B8FK's forecast earnings growth is above the savings rate (0.8%).

수익 vs 시장: Insufficient data to determine if B8FK's earnings are forecast to grow faster than the German market

고성장 수익: Insufficient data to determine if B8FK's earnings are expected to grow significantly over the next 3 years.

수익 대 시장: Insufficient data to determine if B8FK's revenue is forecast to grow faster than the German market.

고성장 수익: Insufficient data to determine if B8FK's revenue is forecast to grow faster than 20% per year.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: Insufficient data to determine if B8FK's Return on Equity is forecast to be high in 3 years time

Biofrontera 미래 성장

Future 기준 확인 0/6

주요 정보

최근 미래 성장 업데이트

Biofrontera AG Continues to Adhere to Its Forecast for Fiscal Year 2022

Biofrontera AG Provides Earnings Guidance for the Year 2022

Biofrontera AG Proposes Revenue Guidance for the Year 2022

Forecast to breakeven in 2024

Price target decreased to €5.50

Consensus EPS estimates fall to -€0.21

Recent updates

Biofrontera AG (ETR:B8FK) Surges 30% Yet Its Low P/S Is No Reason For Excitement

New major risk - Financial position

Second quarter 2024 earnings released: €0.023 loss per share (vs €0.12 profit in 2Q 2023)

Biofrontera AG to Report First Half, 2024 Results on Sep 30, 2024

Biofrontera AG, Annual General Meeting, Aug 28, 2024

New major risk - Shareholder dilution

Investor sentiment deteriorates as stock falls 19%

First quarter 2024 earnings released: €0.04 loss per share (vs €1.05 loss in 1Q 2023)

Biofrontera AG (ETR:B8FK) Not Doing Enough For Some Investors As Its Shares Slump 47%

Biofrontera AG to Report Q1, 2024 Results on May 31, 2024

Full year 2023 earnings released: €0.01 loss per share (vs €0.77 loss in FY 2022)

Biofrontera AG to Report Fiscal Year 2023 Results on Apr 30, 2024

Why Investors Shouldn't Be Surprised By Biofrontera AG's (ETR:B8F) 30% Share Price Plunge

We're Keeping An Eye On Biofrontera's (ETR:B8F) Cash Burn Rate

Biofrontera AG to Report Q3, 2023 Results on Nov 28, 2023

Biofrontera AG to Report First Half, 2023 Results on Aug 31, 2023

Biofrontera Launches Novel Belixos Active Care

Biofrontera AG to Report Q1, 2023 Results on May 31, 2023

Biofrontera AG Completes Patient Recruitment of Ameluz Phase I Trial

Biofrontera AG, Annual General Meeting, Jun 20, 2023

Biofrontera AG Announces Executive Appointments to Biofrontera UK Ltd

Biofrontera AG Continues to Adhere to Its Forecast for Fiscal Year 2022

Biofrontera AD Shares - Sponsored to Be Deleted from OTC Equity

Biofrontera AG Appoints Prof. Dr. Karin Lergenmüller to the Supervisory Board

Biofrontera AG Announces Appointment of Pilar de la Huerta Martinez as New Chief Financial Officer

Biofrontera AG to Report First Half, 2022 Results on Aug 23, 2022

Biofrontera AG Appoints Paul Böckmann to Management Board

Biofrontera AG to Report Q1, 2022 Results on May 17, 2022

Biofrontera AG Provides Earnings Guidance for the Year 2022

Biofrontera AG to Report Fiscal Year 2021 Results on Apr 28, 2022

Biofrontera AG Proposes Revenue Guidance for the Year 2022

Biofrontera AG Resigns Franca Ruhwedel as Member of the Supervisory Board

Biofrontera AG Decides to Delist ADS from Nasdaq

Biofrontera AG Announces Progress of Phase Iii Study for the Treatment of sBCC with Ameluz®

Forecast to breakeven in 2024

Biofrontera AG Enrolls First Patient to Phase IIb Clinical Study Evaluating Ameluz® / BF-RhodoLED® for Acne

Here's Why It's Unlikely That Biofrontera AG's (ETR:B8F) CEO Will See A Pay Rise This Year

Price target decreased to €5.50

Consensus EPS estimates fall to -€0.21

No longer forecast to breakeven

Third quarter 2021 earnings released: €0.095 loss per share (vs €0.13 loss in 3Q 2020)

Second quarter 2021 earnings released: €0.07 loss per share (vs €0.001 loss in 2Q 2020)

Biofrontera AG Re-Affirms Earnings Guidance for the Year 2021

Biofrontera AG Provides Update on Clinical Developments

Price target increased to €6.80

Does Biofrontera (ETR:B8F) Have A Healthy Balance Sheet?

Consensus forecasts updated

First quarter 2021 earnings released: €0.09 loss per share (vs €0.14 loss in 1Q 2020)

Price target decreased to €6.90

Biofrontera AG (ETR:B8F) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Full year 2020 earnings released: €0.24 loss per share (vs €0.17 loss in FY 2019)

Biofrontera AG Provides Earnings Guidance for the Year 2021

Price target raised to €10.33

Biofrontera AG to Report Fiscal Year 2020 Final Results on Apr 12, 2021

CFO & Member of the Executive Board has left the company

Biofrontera AG Submits Study Report of Pharmacokinetics Study to FDA

New 90-day low: €2.82

Biofrontera AG Announces Management Changes

Price target raised to €8.55

New 90-day high: €3.37

New 90-day low: €2.83

Third quarter 2020 earnings released: €0.11 loss per share

New 90-day low: €2.87

Biofrontera AG Receives Reasons from the German Federal Court of Justice for Overturning Ruling of the Cologne Higher Regional Court

Biofrontera AG Reports Completion of the Clinical Phase of the Pharmacokinetics Study

Biofrontera AG Announces German Federal Supreme Court Overturns Ruling of the Cologne Higher Regional Court

Biofrontera AG(XTRA:B8F) dropped from S&P Global BMI Index

Price target raised to €7.77

Earnings released